Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata

THRIVE-AA2 Study Met Primary Endpoint for Scalp Hair Regrowth Key Secondary Endpoint Met for Patient Reported Outcome on Hair Satisfaction Key Secondary Endpoint Met for Hair Regrowth as Early as 12 Weeks CTP-543 Has Potential to be Best-in-Cla